Supernus Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 6/6
Supernus Pharmaceuticals has a total shareholder equity of $921.5M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $1.3B and $356.2M respectively. Supernus Pharmaceuticals's EBIT is $13.4M making its interest coverage ratio -1.7. It has cash and short-term investments of $254.9M.
Key information
0%
Debt to equity ratio
US$0
Debt
Interest coverage ratio | -1.7x |
Cash | US$254.87m |
Equity | US$921.52m |
Total liabilities | US$356.16m |
Total assets | US$1.28b |
Recent financial health updates
Recent updates
Financial Position Analysis
Short Term Liabilities: S49's short term assets ($493.1M) exceed its short term liabilities ($290.2M).
Long Term Liabilities: S49's short term assets ($493.1M) exceed its long term liabilities ($66.0M).
Debt to Equity History and Analysis
Debt Level: S49 is debt free.
Reducing Debt: S49 has no debt compared to 5 years ago when its debt to equity ratio was 78.2%.
Debt Coverage: S49 has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: S49 has no debt, therefore coverage of interest payments is not a concern.